116 related articles for article (PubMed ID: 4406591)
41. [Treatment of Paget's disease with salmon calcitonin].
Manderlier T; Fuss M; Brauman J; Orloff S; Bergans A; Corvilain J
Rev Rhum Mal Osteoartic; 1977 Jan; 44(1):59-66. PubMed ID: 319520
[No Abstract] [Full Text] [Related]
42. Incidence and sites of bone lesions detected by 99mTc-polyphosphate scans in patients with tumors.
Belliveau RE; Spencer RP
Cancer; 1975 Aug; 36(2):359-63. PubMed ID: 1157007
[TBL] [Abstract][Full Text] [Related]
43. A biochemical approach to the staging of human breast cancer.
Coombes RC; Powles TJ; Gazet JC; Ford HT; Nash AG; Sloane JP; Hillyard CJ; Thomas P; Keyser JW; Marcus D; Zinberg N; Stimson WH; Neville AM
Cancer; 1977 Aug; 40(2):937-44. PubMed ID: 890676
[No Abstract] [Full Text] [Related]
44. [Short term treatment of Paget's disease with porcine calcitonin].
Renier JC; Boasson M; Jallet P; Bernat M
Rev Rhum Mal Osteoartic; 1973 Oct; 40(10):557-63. PubMed ID: 4797550
[No Abstract] [Full Text] [Related]
45. [Calcitonin, calcium lactate-gluconate + potassium phosphate, calcium phosphate: changes induced in the biology of the patient with multiple fractures].
de Bastiani G; Nogarin L; Perusi M
Clin Ortop; 1974; 25(4):199-204. PubMed ID: 4471239
[TBL] [Abstract][Full Text] [Related]
46. Thyrotoxicosis and hypercalcaemia: response to antithyroid drugs and salmon calcitonin.
Woodhouse NJ; Hoare A; Mohamedally SM; Marsden P
Horm Res; 1976; 7(4-5):238-46. PubMed ID: 65311
[TBL] [Abstract][Full Text] [Related]
47. Clinical applications of calcitonin.
Can Med Assoc J; 1971 Aug; 105(3):238-9. PubMed ID: 5563336
[No Abstract] [Full Text] [Related]
48. Treatment of post-menopausal osteoporosis with phosphate and intermittent calcitonin.
Kuntz D; Marie P; Berhel M; Caulin F
Int J Clin Pharmacol Res; 1986; 6(2):157-62. PubMed ID: 3522444
[TBL] [Abstract][Full Text] [Related]
49. Newer agents in treating Paget's disease of bone.
Goldfield EB
Geriatrics; 1974 Dec; 29(12):61-9. PubMed ID: 4279196
[No Abstract] [Full Text] [Related]
50. Effects of prolonged thyrocalcitonin administration on Paget's disease of bone.
Haddad JG; Birge SJ; Avioli LV
N Engl J Med; 1970 Sep; 283(11):549-55. PubMed ID: 5450609
[No Abstract] [Full Text] [Related]
51. [BONE METASTASES IN PRIMARY LIVER CARCINOMA].
PAYET M; SANKALE M; CAVE L; MOULANIER M; PENE P; BOURGEADE A; LECADRE G
Presse Med (1893); 1965 Jan; 73():115-8. PubMed ID: 14229061
[No Abstract] [Full Text] [Related]
52. Osteoblastic metastases from a hypernephroma.
Reidy JF
Br J Radiol; 1975 Mar; 48(567):225-7. PubMed ID: 1125551
[No Abstract] [Full Text] [Related]
53. [Short-term biological effects of synthetic salmon calcitonin in Paget's disease. Influence of posology].
Chapuy MC; Meunier P; Terrier M; David L; Vignon G
Pathol Biol (Paris); 1975 May; 23(5):349-59. PubMed ID: 172838
[TBL] [Abstract][Full Text] [Related]
54. [Diagnosis of bone metastases with special reference to the methods of clinical chemistry].
Burkhardt H; Wepler R; Burkhardt F; Rommel K
Med Welt; 1975 Aug; 26(31-32):1411-5. PubMed ID: 1165713
[No Abstract] [Full Text] [Related]
55. Effects of prolonged administration of porcine calcitonin in postmenopausal osteoporosis.
Jowsey J; Riggs BL; Goldsmith RS; Kelly PJ; Arnaud CD
J Clin Endocrinol Metab; 1971 Nov; 33(5):752-8. PubMed ID: 4942159
[No Abstract] [Full Text] [Related]
56. Bone cell activities and calcium-regulating hormones.
Mizuno K; Tanaka J; Sumi M; Hirohata K
Kobe J Med Sci; 1981 Dec; 27(6):251-61. PubMed ID: 6965270
[No Abstract] [Full Text] [Related]
57. Osseous metastasis: its relationship to primary carcinoma of the head and neck.
Arlen M; Wanebo H; Guerra O; Higinbotham N; Huvos A; Miller T
Am J Surg; 1974 Oct; 128(4):568-72. PubMed ID: 4423265
[No Abstract] [Full Text] [Related]
58. Sites and modes of action of an estrogen-gestagen combination on calcium and phosphate metabolism in postmenopausal osteoporosis.
Caniggia A; Gennari C
Clin Orthop Relat Res; 1972; 85():184-92. PubMed ID: 4556555
[No Abstract] [Full Text] [Related]
59. [Human calcitonin in the treatment of symptomatic Paget's disease].
Mathä R; Kovarik J; Woloszczuk W; Plenk H; Willvonseder R; Böhler N; Seidl G; Höfer R
Aktuelle Gerontol; 1983 Jan; 13(1):10-4. PubMed ID: 6131616
[TBL] [Abstract][Full Text] [Related]
60. Urinary hydroxyproline excretion in patients with cancer.
Guzzo CE; Pachas WN; Pinals RS; Krant MJ
Cancer; 1969 Aug; 24(2):382-7. PubMed ID: 5796782
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
